Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 974
countries
28
conditions
2 106

15 trials match your criteria

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib

Metastatic neoplasm

Recruiting

Evaluation of drug combination therapy (olaparib, nilotinib, tremelimumab, and durvalumab) for patients with advanced or metastatic solid tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Prolymphocytic leukaemia+2

Recruiting

Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Philadelphia positive chronic myeloid leukaemia

Not recruiting

Study on the Bioavailability of Nilotinib in Healthy Individuals with Chronic Myelogenous Leukemia (CML)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Nilotinib

Chronic myeloid leukaemia

Not recruiting

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib

Chronic myeloid leukaemia (in remission)

Not recruiting

Study on Stopping Nilotinib for Chronic Myeloid Leukemia Patients After Previous Unsuccessful Attempts to Stop Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib

Chronic myeloid leukaemia

Not recruiting

Study on Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: Comparing Dasatinib, Imatinib, Nilotinib, and Bosutinib Strategies

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib

Chronic myeloid leukaemia

Not recruiting

Study of treatment discontinuation with nilotinib and asciminib in adults with chronic myeloid leukemia to achieve treatment-free remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib

Chronic myeloid leukaemia (in remission)

Not recruiting

Study on Stopping Nilotinib, Imatinib, and Dasatinib in Patients with Chronic Myeloid Leukemia in Deep Remission

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib

Chronic myeloid leukaemia

Not recruiting

Study on the Effectiveness of Asciminib and Imatinib for Patients with Chronic Myelogenous Leukemia Not Responding to Imatinib

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib

Chronic myeloid leukaemia

Not recruiting

Study of dose reduction strategy for tyrosine kinase inhibitors (imatinib, ponatinib, bosutinib, nilotinib, dasatinib) in patients with chronic myeloid leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib

Sarcoma

Not recruiting

Study on Advanced Soft-Tissue Sarcoma: Testing Futibatinib and Drug Combination for Patients with Unresectable or Metastatic Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capmatinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.